

Syrma SGS Technology Limited

August 09, 2023

Credit Update:

Syrma SGS Technology Limited (SSTL; CARE A+; Positive/ CARE A1+) has submitted to the stock exchanges on August 01, 2023, that the company has entered into a share purchase agreement and a shareholders' agreement with Johari Digital Healthcare Limited (JDHL) and the promoters of JDHL, in connection with, inter alia, acquisition of 51% of the shareholding of JDHL. The acquisition is expected to be completed before September 30, 2023.

The cost of acquisition is Rs. 257.5 crore of which about Rs. 229.5 crore would be upfront payment and Rs. 28 crore would be deferred payment based on profitability milestones. The acquisition is expected to be funded entirely out of cash and internal accruals and no debt is expected to be raised. SSTL had unutilized balance of IPO proceeds of about Rs. 578.23 crore as on June 30, 2023, of which Rs. 191.14 crore is earmarked for General Corporate Purpose (GCP). The company is expected to utilize this amount earmarked for GCP for this acquisition and the balance is expected to be funded out of internal accruals. The acquisition is not expected to have a significant impact on the capital structure of the company.

JDHL is an electronic medical device manufacturer. The company designs, develops, engineers, and manufactures medical devices for global markets. Majority of the products of JHPL is box-builds and mainly caters to US and Europe markets. The facility is compliant with Medical Device Single Audit Program (MDSAP), The United States Food and Drug Administration (US FDA), and Good Manufacturing Practices (GMP). The company has a manufacturing facility in India and R&D centers in Europe and IIT Jodhpur. The acquisition is expected to enable SSTL gain access to facilities with export certifications, expand its product profile with addition of about 145+ commercialized products of JHPL and over the long-term leverage the design and development capabilities of JHPL.

JHPL has recorded a PBILDT of Rs. 58 crore on a TOI of Rs. 162 crore in FY23 as against a PBILDT of Rs. 34 crore on a TOI of Rs. 89 crore in FY22. JHPL does not have any long-term debt. SSTL has recorded a PBILDT of Rs. 187.77 crore on a TOI of Rs. 2048 crore in FY23 and Rs. 36.94 crore on a TOI of Rs. 601 crore in Q1FY24.

CARE Ratings has taken note of the expected acquisition and will continue to monitor the developments of the same.

Please refer to the following link for the previous press release that captures key rating factors and rating sensitivities: [Click here](#)

Contact Us

<p>Media Contact</p> <p>Mradul Mishra Director CARE Ratings Limited Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in</p> <p>Relationship Contact</p> <p>Pradeep Kumar V Senior Director CARE Ratings Limited Phone: +91-98407 54521 E-mail: pradeep.kumar@careedge.in</p>	<p>Analytical Contacts</p> <p>Sandeep P Director CARE Ratings Limited Phone: +91 44-2849 7812 E-mail: sandeep.prem@careedge.in</p> <p>Abitha Prabakaran Assistant Director CARE Ratings Limited Phone: +91-44-2850 1000 E-mail: abitha.prabakaran@careedge.in</p> <p>Bhargavi R Lead Analyst CARE Ratings Limited E-mail: bhargavi.r@careedge.in</p>
--	---

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,
please visit www.careedge.in**